secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kailera Therapeutics, Inc. (KLRA)
CIK:        0002096997
Form:       8-K
Filed at:   2026-08-12T20:20:55+00:00
Accession:  0001193125-26-346919
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kailera Q2 net loss widens to $111.3M; cash $1.17B funds into mid-2028
----------------------------------------------------------------------

- Net loss $111.3M in Q2 2026 vs $28.9M in Q2 2025; R&D expense $101.1M (up from $19.5M).
- Cash, equivalents and marketable securities $1,171.8M, expected to fund operations into mid-2028.
- Ribupatide oral IND active; global Phase 3 obesity trial initiations planned for H1 2027.
- Phase 2b high-dose ribupatide injection trial fully enrolled (264 pts); data expected mid-2027.
- Appointed Nur Nicholson as CTO and Kathleen Tregoning as Chief Corporate Affairs Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/0001193125-26-346919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/ck0002096997-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-346919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer